Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

  • Min Wu Chao (Contributor)
  • Li Hsun Chang (Contributor)
  • Huang Ju Tu (Contributor)
  • Chao-Di Chang (Contributor)
  • Mei-Jung Lai (Contributor)
  • Ying Yi Chen (Creator)
  • Jing-Ping Liou (Creator)
  • Che Ming Teng (Contributor)
  • Shiow-Lin Pan (Contributor)

資料集

Description

Figure S1. Cytotoxic effect of combination HDACi with MEK inhibitors in BxPC-3 and PANC-1 cells. (A, B) BxPC-3 cells were treated with DMSO, MPT0E028 (E028)/SAHA, PD98059 (PD), or MPT0E028/SAHA plus PD98059 with indicated concentration for 72 h. (C, D) PANC-1 cells were treated with DMSO, MPT0E028/SAHA, trametinib (T), or MPT0E028/SAHA plus trametinib with indicated concentration for 72 h. Left panels: Cell viability was determined by MTT assay. Right panels: Combination index (CI) and fraction affected (Fa) are calculated by CompuSyn software. T0.1 and T1 were represented here as trametinib 0.1 μM and 1 μM. (TIF 440 kb)
可用日期2019
發行者Figshare

存取資料集

引用此